Xenex Disinfection Services LLC

Xenex Disinfection Services LLC provides advanced disinfection solutions for healthcare environments, utilizing Pulsed Xenon UV technology to effectively neutralize harmful pathogens, ensuring safer spaces for patients and healthcare workers. Founded in 2009 and headquartered in San Antonio, US, Xenex Disinfection Services LLC specializes in innovative disinfection solutions. The company was established to address the critical need for infection prevention in healthcare settings. Brian Cruver founded the company, while Morris Miller currently serves as CEO.

In 2018, the company raised USD 4. 77 mn in a VENTURE DEBT funding round, contributing to its total of USD 38. 00 mn raised across 6 deals since inception. Xenex Microbial Reduction specializes in advanced disinfection products, including its flagship LightStrike® system that employs patented Pulsed Xenon UV technology.

The product range includes the LightStrike+ MXSUV1-FT and MXSUV1-SL models, as well as the LightStrike6 LSMUV6-FT/LSMUV6-SL units, designed for efficient room turnover. The company also offers a handheld LED unit and a digital tracking system, TrackMate, to enhance workflow in healthcare facilities. Targeting hospitals and healthcare providers, Xenex’s products are used across North America, Europe, and various global markets. Xenex generates revenue through direct sales of disinfection products and services to healthcare facilities, operating on a B2B model.

Transactions typically involve upfront purchases of disinfection units along with options for ongoing support, training, and maintenance, such as Xtra Care Plans. These tailored agreements ensure healthcare facilities receive effective solutions for pathogen reduction. Xenex aims to expand its product offerings and market reach. The company is focused on developing new models of its disinfection systems, with plans for introduction in the upcoming year.

Additionally, Xenex intends to penetrate new geographic markets, particularly in Europe and Asia, by the end of 2024. The recent funding of USD 4. 77 mn raised in October 2018 through a VENTURE DEBT financing round will support these growth initiatives, facilitating product development and market expansion efforts.